Researchers have announced that an experimental drug, added to a standard chemotherapy treatment, has succeeded in improving survival chances for patients with one of the most deadly forms of female reproductive system cancer. This was demonstrated in a mid-stage clinical trial conducted in Belarus. The study included 30 women with ovarian cancer who had stopped responding to platinum-based chemotherapy, which is used as a first-line treatment, and who had high levels of a cancer-related blood protein known as CA-125. All participants in the study received standard treatment with the drug gemcitabine, while half of them also received the drug 'Elinagen', produced by 'CureLab Oncology', in the form of intramuscular injections administered once a week. The results showed that those who received 'Elinagen' lived significantly longer, with a median survival time exceeding 25 months, compared to about 13 months for those who received only gemcitabine. The lead researcher, Dr. Sergey Krasny from the N.N. Alexandrov National Cancer Center in Minsk, Belarus, stated: 'What is remarkable about the results is not only the increase in survival time, but also that it is achieved without additional toxicity'.